Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells

Cancer Gene Therapy

Volumn 11, Issue 2, 2004, Pages 148-155

  Hsieh, Chia Ling ^a   Gardner, Thomas A ^b   Miao, Li ^c   Balian, Gary ^c   Chung, Leland W K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Animal model; Cotargeting gene therapy; Human prostate cancer bone metastasis; Osteocalcin; Stromal epithelial interaction; Tumor microenvironment interaction

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; CELL PROTEIN; GANCICLOVIR; LUCIFERASE; OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER MODEL; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CELL INTERACTION; CELL ISOLATION; CHIMERA; CONTROLLED STUDY; COTARGETING GENE THERAPY; EPITHELIUM CELL; GENE TARGETING; GENE THERAPY; GENOTYPE ENVIRONMENT INTERACTION; GROWTH INHIBITION; HSV TK GENE; HUMAN; HUMAN CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; STROMA CELL; TRANSGENE; TUMOR GROWTH; TUMOR MODEL;

ADENOVIRIDAE; ANIMALS; BONE MARROW CELLS; CELL LINE, TUMOR; CHIMERA; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GANCICLOVIR; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; OSTEOBLASTS; OSTEOCALCIN; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; STROMAL CELLS; THYMIDINE KINASE;

ADENOVIRIDAE; ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0942268828     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700665     Document Type: Article

References (49)

1. Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation. 2002;70:506-521.
2. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Diffrentiation. 2002;70: 473-485.
3. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54:2577-2581.
4. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002;62: 3298-3307.
5. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet. 2001;10:1907-1913.
6. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer. 1994;56:681-688.
7. Cleary KR, Batsakis JG. Undifferentiated carcinoma with lymphoid stroma of the major salivary glands. Ann Otol Rhinol Laryngol. 1990;99:236-238.
8. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994;57:406-412.
9. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY, von Eschenbach AC. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer. 1989;43:1179-1187.
10. Nemeth JA, Harb JF, Barroso Jr U, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res. 1999;59:1987-1993.
11. Chung LW, Gleave ME, Hsieh JT, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surv. 1991;11:91-121.
12. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol. 2001;166:2472-2483.
13. Chung LW, Li W, Gleave ME, et al. Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl. 1992;16H:99-105.
14. Hsieh CL, Chung LW. New prospectives of prostate cancer gene therapy: molecular targets and animal models. Crit Rev Eukaryot Gene Expression. 2001;11:77-120.
15. Yeung F, Chung LW. Molecular basis of co-targeting prostate tumor and stroma. J Cell Biochem Suppl. 2002;38:65-72.
16. Farnsworth WE. Prostate stroma: physiology. Prostate. 1999;38:60-72.
17. Chung LW. The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv. 1995;23: 33-42.
18. Nemeth JA, Roberts JW, Mullins CM, Cher ML. Persistence of human vascular endothelium in experimental human prostate cancer bone tumors. Clin Exp Metastasis. 2000;18:231-237.
19. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 2001;61:6012-6019.
20. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336-341.
21. Diduch DR, Coe MR, Joyner C, Owen ME, Balian G. Two cell lines from bone marrow that differ in terms of collagen synthesis, osteogenic characteristics, and matrix mineralization. J Bone Joint Surg Am. 1993;75:92-105.
22. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol. 1995;3:207-220.
23. Bosch RJ, Woolf AS, Fine LG. Gene transfer into the mammalian kidney: direct retrovirus-transduction of regenerating tubular epithelial cells. Exp Nephrol. 1993;1:49-54.
24. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem. 2000;275:40846-40855.
25. Wu TT, Sikes RA, Cui Q, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer. 1998;77:887-894.
26. Hsieh CL, Yang L, Miao L, et al. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Res. 2002;62:3084-3092.
27. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997;4:244-251.
28. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62:1030-1035.
29. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor 1 and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20:833-841.
30. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 2002;62:854-859.
31. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol. 2001;159:651-659.
32. Ferrer FA, Miller LJ, Lindquist R, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999;54:567-572.
33. Kassen AE, Sensibar JA, Sintich SM, Pruden SJ, Kozlowski JM, Lee C. Autocrine effect of DHT on FGF signaling and cell proliferation in LNCaP cells: role of heparin/heparandegrading enzymes. Prostate. 2000;44:124-132.
34. Ropiquet F, Berthon P, Villette JM, Le Brun G, Maitland NJ, Cussenot O, et al. Constitutive expression of FGF2/bFGF in non-tumorigenic human prostatic epithelial cells results in the acquisition of a partial neoplastic phenotype. Int J Cancer. 1997;72:543-547.
35. Sitaras NM, Sariban E, Bravo M, Pantazis P, Antoniades HN. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res. 1988;48:1930-1935.
36. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44:77-87.
37. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer. 2001;93:507-515.
38. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst. 2002;94:17-25.
39. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999;39:246-261.
40. Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate. 2001;47:212-221.
41. Pollard M. Lobund-Wistar rat model of prostate cancer in man. Prostate. 1998;37:1-4.
42. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977;37:1929-1933.
43. Lubaroff DM, Canfield L, Rasmussen GT, Reynolds CW. An animal model for the study of prostate carcinoma. Natl. Cancer Inst Monogr. 1978:275-281.
44. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA. 1995;92:3439-3443.
45. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA. 1994;91:11236-11240.
46. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276-5281.
47. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
48. Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res. 2001;61:6328-6330.
49. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res. 2001;61:6592-6600.